Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 25
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Tipo de documento
Assunto da revista
País de afiliação
Intervalo de ano de publicação
1.
Respiration ; 102(5): 341-350, 2023.
Artigo em Inglês | MEDLINE | ID: mdl-36724753

RESUMO

BACKGROUND: Mechanical insufflation/exsufflation (MI-E) devices are often prescribed to patients with inefficient cough and recurrent infections, but their use in the home setting is not well characterized. OBJECTIVE: The objective of this study was to report a real-life experience and identify factors that are associated with home MI-E use in adult patients. METHODS: This is a cross-sectional observational study of adult subjects with neurological disease using MI-E at home for more than 3 months. RESULTS: A total of 43 patients were included. Median age (interquartile range) was 48 (31-64) years. The most common diagnosis was muscular dystrophy (n = 15), followed by multiple sclerosis (n = 7) and amyotrophic lateral sclerosis (n = 7). 24 subjects (56%) reported using the MI-E at least once weekly. Based on device data downloads, the median objective use was 23% of days analysed (approximately 2 times per week). The vast majority (94%) of all participants reported using the device at least daily during an infectious episode, while 62% reported having used the device in emergency situations such as bronchoaspiration. Reported use correlated well with objective use (r = 0.82). Most subjects reported an improvement in their respiratory health (64%) and were satisfied with the device (78%). Higher reported and objective use were associated with increased symptoms (p = 0.001) and higher satisfaction with the device (p = 0.008). We found no association between frequency of use and baseline cough peak flow (CPF), bulbar impairment, non-invasive ventilation use, living environment, or supervised administration. CONCLUSION: Regular home MI-E use was associated with greater symptom burden and overall satisfaction with the device and was not influenced by baseline CPF. Patients without substantial bronchorrhea might not use the MI-E regularly but might still need to use the device at home during acute events. Therefore, familiarity with the MI-E via appropriate and repeated practical training is crucial.


Assuntos
Tosse , Insuflação , Humanos , Adulto , Pessoa de Meia-Idade , Estudos Transversais , Suíça , Respiração Artificial
2.
Respiration ; 102(2): 120-133, 2023.
Artigo em Inglês | MEDLINE | ID: mdl-36566741

RESUMO

BACKGROUND: Lung function impairment persists in some patients for months after acute coronavirus disease 2019 (COVID-19). Long-term lung function, radiological features, and their association remain to be clarified. OBJECTIVES: We aimed to prospectively investigate lung function and radiological abnormalities over 12 months after severe and non-severe COVID-19. METHODS: 584 patients were included in the Swiss COVID-19 lung study. We assessed lung function at 3, 6, and 12 months after acute COVID-19 and compared chest computed tomography (CT) imaging to lung functional abnormalities. RESULTS: At 12 months, diffusion capacity for carbon monoxide (DLCOcorr) was lower after severe COVID-19 compared to non-severe COVID-19 (74.9% vs. 85.2% predicted, p < 0.001). Similarly, minimal oxygen saturation on 6-min walk test and total lung capacity were lower after severe COVID-19 (89.6% vs. 92.2%, p = 0.004, respectively, 88.2% vs. 95.1% predicted, p = 0.011). The difference for forced vital capacity (91.6% vs. 96.3% predicted, p = 0.082) was not statistically significant. Between 3 and 12 months, lung function improved in both groups and differences in DLCO between non-severe and severe COVID-19 patients decreased. In patients with chest CT scans at 12 months, we observed a correlation between radiological abnormalities and reduced lung function. While the overall extent of radiological abnormalities diminished over time, the frequency of mosaic attenuation and curvilinear patterns increased. CONCLUSIONS: In this prospective cohort study, patients who had severe COVID-19 had diminished lung function over the first year compared to those after non-severe COVID-19, albeit with a greater extent of recovery in the severe disease group.


Assuntos
COVID-19 , Insuficiência Respiratória , Humanos , Estudos Prospectivos , Suíça/epidemiologia , Pulmão/diagnóstico por imagem
3.
Rev Med Suisse ; 19(850): 2153-2158, 2023 Nov 15.
Artigo em Francês | MEDLINE | ID: mdl-37966146

RESUMO

Only severe hypoxemia at rest in COPD patients has strong recommendations for long-term oxygen therapy. It is accepted that oxygen should be prescribed if PaO2 is ≤ 7,3 kPa (55 mmHg), or if PaO2 is ≤ 8 kPa (60 mmHg) in the presence of signs of pulmonary hypertension or a hematocrit ≥ 55 %. In Switzerland, prescription is governed by the LiMA (Liste des moyens et appareils) and the patient can obtain supplies from a health care provider or directly from the provider. The most suitable device taking patient's oxygen needs and mobility into account must be chosen. O2 prescription entails risks for the patient that must be known to the prescriber. This article presents the different aspects of long-term home oxygen therapy.


Seule l'hypoxémie sévère au repos chez le patient BPCO possède de solides recommandations pour la prescription d'oxygène au long cours. L'hypoxémie sévère est définie par une pression partielle en oxygène dans le sang artériel (PaO2) ≤ 7,3 kPa (55 mmHg) ou une PaO2 ≤ à 8 kPa (60 mmHg) en présence de signes d'hypertension pulmonaire ou d'un taux d'hématocrite ≥ 55 %. En Suisse, sa prescription est régie par la liste des moyens et appareils (LiMA) et le patient peut s'approvisionner auprès d'un prestataire de soins ou directement auprès du fournisseur. Le dispositif le mieux adapté à chaque patient tenant compte de son besoin en oxygène et de sa mobilité doit être choisi. Sa prescription entraîne des risques pour le patient, qui doivent être connus du prescripteur. Cet article expose les différents aspects de l'oxygénothérapie au long cours à domicile.


Assuntos
Hipertensão Pulmonar , Oxigenoterapia , Humanos , Oxigênio/uso terapêutico , Hipóxia/etiologia , Hipóxia/terapia , Hipóxia/diagnóstico , Hipertensão Pulmonar/terapia , Prescrições
4.
Respiration ; 101(10): 939-947, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-36030774

RESUMO

BACKGROUND: Long-term noninvasive ventilation (LTNIV) is widely used in patients with chronic hypercapnic respiratory failure (CHRF) related to COPD. Prognosis of these patients is however poor and heterogenous. RESEARCH QUESTION: In COPD patients under LTNIV for CHRF, is it possible to identify specific phenotypes which are predictive of probability of pursuing NIV and survival? STUDY DESIGN AND METHODS: A latent class analysis was performed in a COPD population under LTNIV included in a comprehensive database of patients in the Geneva Lake area, to determine clinically relevant phenotypes. The observation period of this subgroup of COPD was extended to allow assessment of survival and/or pursuit of NIV for at least 2 years after inclusion. A logistic regression was conducted to generate an equation accurately attributing an individual patient to a defined phenotype. The identified phenotypes were compared on a series of relevant variables, as well as for probability of pursuing NIV or survival. A competitive risk analysis allowed to distinguish death from other causes of cessation of NIV. RESULTS: Two phenotypes were identified: a "respiratory COPD" profile with very severe airway obstruction, a low or normal body mass index, and a low prevalence of comorbidities and a "systemic COPD" profile of obese COPDs with moderate airway obstruction and a high rate of cardiovascular and metabolic comorbidities. The logistic regression correctly classified 95.7% of patients studied. Probability of pursuing NIV and survival were significantly related to these phenotypes, with a poorer prognosis for "respiratory COPD." Probability of death 5 years after implementing NIV was 22.3% (95% CI: 15.4-32.2) for "systemic COPD" versus 47.2% (37.4-59.6) for "respiratory COPD" (p = 0.001). CONCLUSION: The two distinct phenotypes of COPD under LTNIV for CHRF identified appear to be strongly related to prognosis and require further validation in other cohort studies.


Assuntos
Obstrução das Vias Respiratórias , Ventilação não Invasiva , Doença Pulmonar Obstrutiva Crônica , Insuficiência Respiratória , Humanos , Hipercapnia/etiologia , Fenótipo , Doença Pulmonar Obstrutiva Crônica/complicações , Insuficiência Respiratória/etiologia , Insuficiência Respiratória/terapia
5.
Eur Respir J ; 57(4)2021 04.
Artigo em Inglês | MEDLINE | ID: mdl-33419891

RESUMO

BACKGROUND: The infectious coronavirus disease 2019 (COVID-19) pandemic is an ongoing global healthcare challenge. Up to one-third of hospitalised patients develop severe pulmonary complications and acute respiratory distress syndrome. Pulmonary outcomes following COVID-19 are unknown. METHODS: The Swiss COVID-19 lung study is a multicentre prospective cohort investigating pulmonary sequelae of COVID-19. We report on initial follow-up 4 months after mild/moderate or severe/critical COVID-19 according to the World Health Organization severity classification. RESULTS: 113 COVID-19 survivors were included (mild/moderate n=47, severe/critical n=66). We confirmed several comorbidities as risk factors for severe/critical disease. Severe/critical disease was associated with impaired pulmonary function, i.e. diffusing capacity of the lung for carbon monoxide (D LCO) % predicted, reduced 6-min walk distance (6MWD) and exercise-induced oxygen desaturation. After adjustment for potential confounding by age, sex and body mass index (BMI), patients after severe/critical COVID-19 had a D LCO 20.9% pred (95% CI 12.4-29.4% pred, p=0.01) lower at follow-up. D LCO % pred was the strongest independent factor associated with previous severe/critical disease when age, sex, BMI, 6MWD and minimal peripheral oxygen saturation at exercise were included in the multivariable model (adjusted odds ratio per 10% predicted 0.59, 95% CI 0. 37-0.87; p=0.01). Mosaic hypoattenuation on chest computed tomography at follow-up was significantly associated with previous severe/critical COVID-19 including adjustment for age and sex (adjusted OR 11.7, 95% CI 1.7-239; p=0.03). CONCLUSIONS: 4 months after severe acute respiratory syndrome coronavirus 2 infection, severe/critical COVID-19 was associated with significant functional and radiological abnormalities, potentially due to small-airway and lung parenchymal disease. A systematic follow-up for survivors needs to be evaluated to optimise care for patients recovering from COVID-19.


Assuntos
COVID-19 , Humanos , Pulmão/diagnóstico por imagem , Estudos Prospectivos , Testes de Função Respiratória , SARS-CoV-2 , Suíça/epidemiologia
6.
Rev Med Suisse ; 17(759): 1992-1999, 2021 Nov 17.
Artigo em Francês | MEDLINE | ID: mdl-34787974

RESUMO

Infection with SARS-CoV-2 can affect multiple organ systems with variable severity and is known to frequently have a major impact on the respiratory system. Symptoms may persist for several months after infection, and are associated with a reduction of lung function, diminished exercise capacity and anomalies on chest CT. Guidelines on the post-acute care of patients with SARS-CoV-2 are now available. Pulmonary rehabilitation plays a central role in the recovery of exercise capacity, notably in severe cases. The role of specific therapies, such as corticosteroids, anti-fibrotics and lung transplantation remains uncertain and needs to be evaluated on a case-by-case basis.


L'infection à SARS-CoV-2 conduit à une atteinte multisystémique de gravité variable, fréquemment avec un impact majeur sur le système respiratoire. Les symptômes peuvent persister plusieurs mois après l'infection initiale. Ils sont parfois associés à une diminution des fonctions pulmonaires et de la capacité à l'effort, ainsi qu'à des anomalies au CT-scan thoracique. Il existe actuellement des recommandations de suivi et de prise en charge des patients atteints par le Covid-19 pour la phase postaiguë. La réhabilitation pulmonaire joue un rôle central dans la récupération de la capacité d'effort, surtout dans les formes sévères. La place des traitements spécifiques des atteintes pulmonaires, notamment les corticostéroïdes, les antifibrotiques et la transplantation, reste encore incertaine et doit être considérée au cas par cas.


Assuntos
COVID-19 , Progressão da Doença , Humanos , SARS-CoV-2 , Tomografia Computadorizada por Raios X
7.
Respiration ; : 1-36, 2020 Dec 10.
Artigo em Inglês | MEDLINE | ID: mdl-33302274

RESUMO

Long-term mechanical ventilation is a well-established treatment for chronic hypercapnic respiratory failure (CHRF). It is aimed at improving CHRF-related symptoms, health-related quality of life, survival, and decreasing hospital admissions. In Switzerland, long-term mechanical ventilation has been increasingly used since the 1980s in hospital and home care settings. Over the years, its application has considerably expanded with accumulating evidence of beneficial effects in a broad range of conditions associated with CHRF. Most frequent indications for long-term mechanical ventilation are chronic obstructive pulmonary disease, obesity hypoventilation syndrome, neuromuscular and chest wall diseases. In the current consensus document, the Special Interest Group of the Swiss Society of Pulmonology reviews the most recent scientific literature on long-term mechanical ventilation and provides recommendations adapted to the particular setting of the Swiss healthcare system with a focus on the practice of non-invasive and invasive home ventilation in adults.

8.
Rev Med Suisse ; 16(715): 2204-2210, 2020 Nov 18.
Artigo em Francês | MEDLINE | ID: mdl-33206477

RESUMO

Chronic cough is a common symptom in the consultation of any general practitioner. It may be idiopathic or reflect a chronic disease. However, cough can become excessive, occurring in response to stimuli that do not usually cause this symptom. This entity is called Cough hypersensitivity syndrome (CHS). Its treatment involves the use of neuromodulator substances that specifically target this hypersensitivity, while maintaining intact the cough reflex, essential for protecting the airways. This review aims to present the current knowledge about the pathophysiology of chronic cough, the initial diagnostic approach that this symptom requires and cough treatments either available or in development.


La toux chronique est un symptôme fréquent dans la consultation de tout médecin généraliste. Elle peut être idiopathique ou refléter une maladie chronique. La toux peut aussi devenir excessive, survenant en réponse à des stimuli qui n'occasionnent pas de toux à l'état normal. Cette entité est désignée comme syndrome d'hypersensibilité à la toux. Son traitement implique l'utilisation de substances neuromodulatrices qui ciblent spécifiquement cette hypersensibilité, tout en maintenant intact le réflexe de toux, essentiel à la protection des voies aériennes. Cet article vise à présenter les connaissances actuelles sur la physiopathologie de la toux chronique, la démarche diagnostique initiale que ce symptôme nécessite et les traitements antitussifs disponibles ou en développement.


Assuntos
Tosse , Hipersensibilidade , Doença Crônica , Tosse/diagnóstico , Tosse/etiologia , Tosse/terapia , Humanos
9.
Rev Med Suisse ; 15(671): 2100-2103, 2019 Nov 13.
Artigo em Francês | MEDLINE | ID: mdl-31742941

RESUMO

Obesity hypoventilation syndrome is an underdiagnosed pathology, whose prevalence is increasing due to the progressively higher prevalence of obesity in the general population. Early detection allows early management and lowers the risk of acute exacerbation, hospitalization and mortality. The diagnosis is done by excluding other, pulmonary or extra pulmonary, reasons of hypercapnia; a nocturnal polygraphy is mandatory to diagnose an associated obstructive sleep apnea syndrome. The pneumological treatment is a ventilatory support by CPAP or biPAP (bilevel Positive Airways Pressure).


Le syndrome obésité-hypoventilation (SOH) est une pathologie sous-diagnostiquée, mais de plus en plus fréquente au vu de l'augmentation de la prévalence de l'obésité. Le dépistage précoce au cabinet du généraliste peut permettre une prise en charge rapide diminuant le risque d'exacerbation aiguë, d'hospitalisation et de mortalité. Le diagnostic repose sur l'exclusion d'autres causes - pulmonaires ou extrapulmonaires - d'hypercapnie ; une polygraphie nocturne est utile au diagnostic de syndrome des apnées obstructives du sommeil (SAOS), pathologie souvent associée. Le traitement pneumologique consiste en un support ventilatoire par CPAP ou biPAP (bilevel Positive Airways Pressure).


Assuntos
Síndrome de Hipoventilação por Obesidade/terapia , Pressão Positiva Contínua nas Vias Aéreas , Humanos , Obesidade/complicações , Síndrome de Hipoventilação por Obesidade/complicações
10.
Rev Med Suisse ; 14(627): 2060-2065, 2018 Nov 14.
Artigo em Francês | MEDLINE | ID: mdl-30427599

RESUMO

Chronic hypercapnic respiratory failure is essentially a ventilatory failure. Noninvasive ventilation (NIV ) reduces the work of breathing, improves pulmonary compliance and alveolar ventilation, corrects gas exchange disorders and improves dyspnoea. However, treatment efficacy depends on the underlying pathology, on correct timing and on patient compliance. In this context, the principal role of the primary care physician is to search for, at every visit of at risk patients, signs and symptoms of ventilatory failure and to refer the patient to a respiratory care specialist. He also plays a role in the follow up of patients under noninvasive ventilation for the detection of clinical parameters suggesting NIV failure.


L'insuffisance respiratoire hypercapnique chronique est essentiellement une défaillance ventilatoire. La ventilation non invasive (VNI) diminue le travail des muscles respiratoires, augmente la compliance thoracique, améliorant ainsi la dyspnée et les troubles des échanges gazeux. Toutefois, l'efficacité du traitement dépend de la pathologie sous-jacente, du bon timing d'initiation et de la compliance du patient. Dans ce contexte, le rôle principal du médecin de premier recours consiste à rechercher, lors de chaque visite médicale de patients à risque, des signes et symptômes de défaillance ventilatoire qui nécessitent de référer le patient à un pneumologue. Son rôle est aussi important dans le suivi des patients ventilés pour la détection précoce des paramètres cliniques suggérant un échec de VNI.


Assuntos
Ventilação não Invasiva , Doença Pulmonar Obstrutiva Crônica , Insuficiência Respiratória , Humanos , Doença Pulmonar Obstrutiva Crônica/terapia , Insuficiência Respiratória/terapia
11.
Rev Med Suisse ; 12(539): 1942-1947, 2016 Nov 16.
Artigo em Francês | MEDLINE | ID: mdl-28696635

RESUMO

Persistent pneumonias are frequent both in hospital and primary care settings. Several parameters have to be taken into account. Firstly the appropriateness of treatment; secondly the immune status of the host; and finally infectious complications need to be ruled out. Several non-infectious diagnoses can mimic a persistent infiltrate, such as neoplastic disorders, organising pneumonias, interstitial disorders and drug - or radiation-induced lung diseases. Uncommon pathogens will not respond to common treatment, for instance atypical bacteria, mycobacteria, fungi including Pneumocystis as well as viruses. Referral to a pulmonologist should be considered to perform a fiberoptic bronchoscopy.


Une pneumonie qui ne guérit pas est un problème fréquent en pratiques hospitalière et ambulatoire. Il faut prendre en compte plusieurs facteurs devant une telle situation. Premièrement, l'adéquation de l'antibiothérapie; deuxièmement, le statut immunitaire du sujet; finalement toute complication infectieuse du foyer de pneumonie doit être exclue. Une série de diagnostics non infectieux seront évoqués, parmi lesquels une néoplasie, une pneumonie en organisation, une pneumopathie interstitielle, médicamenteuse ou radique. Des pathogènes inhabituels doivent être envisagés face à une pneumonie réfractaire, notamment les germes «atypiques¼, les mycobactéries, les champignons y compris le Pneumocystis et les virus. Un avis pneumologique est indiqué afin de réaliser si nécessaire une bronchoscopie avec lavage bronchoalvéolaire.


Assuntos
Broncoscopia/métodos , Pneumopatias/diagnóstico , Pneumonia/terapia , Diagnóstico Diferencial , Humanos , Pneumonia/diagnóstico , Pneumonia/etiologia
12.
Rev Med Suisse ; 11(491): 1955-60, 2015 Oct 21.
Artigo em Alemão | MEDLINE | ID: mdl-26672262

RESUMO

Breathlessness is frequent in the hospital setting: almost 50% of seriously ill hospitalised patients complain of dyspnoea, and its presence aggravates morbidity and mortality. Evaluation of breathlessness, based on self-report, must be completed with the measurement of vital signs and with a search for clinical signs of serious problems - desaturation, stridor, use of accessory muscles or alteration of mental status - that need urgent treatment. After this first therapeutic step, the diagnostic strategy consists of a multidisciplihary approach to determine the physiopathological mechanisms of dyspnoea that will determinate its final management.


Assuntos
Dispneia/diagnóstico , Hospitalização , Sinais Vitais/fisiologia , Dispneia/epidemiologia , Dispneia/terapia , Humanos , Comunicação Interdisciplinar , Sons Respiratórios/etiologia
13.
BMJ Open Respir Res ; 9(1)2022 04.
Artigo em Inglês | MEDLINE | ID: mdl-35459694

RESUMO

BACKGROUND: The Clinical Frailty Scale (CFS) is increasingly used for clinical decision making in acute care but little is known about frailty after COVID-19. OBJECTIVES: To investigate frailty and the CFS for post-COVID-19 follow-up. METHODS: This prospective multicentre cohort study included COVID-19 survivors aged ≥50 years presenting for a follow-up visit ≥3 months after the acute illness. Nine centres retrospectively collected pre-COVID-19 CFS and prospectively CFS at follow-up. Three centres completed the Frailty Index (FI), the short physical performance battery (SPPB), 30 s sit-to-stand test and handgrip strength measurements. Mixed effect logistic regression models accounting for repeated measurements and potential confounders were used to investigate factors associated with post-COVID-19 CFS. Criterion and construct validity were determined by correlating the CFS to other concurrently assessed frailty measurements and measures of respiratory impairment, respectively. RESULTS: Of the 288 participants 65% were men, mean (SD) age was 65.1 (9) years. Median (IQR) CFS at follow-up was 3 (2-3), 21% were vulnerable or frail (CFS ≥4). The CFS was responsive to change, correlated with the FI (r=0.69, p<0.001), the SPPB score (r=-0.48, p<0.001) (criterion validity) and with the St George's Respiratory Questionnaire score (r=0.59, p<0.001), forced vital capacity %-predicted (r=-0.25, p<0.001), 6 min walk distance (r=-0.39, p<0.001) and modified Medical Research Council (mMRC) (r=0.59, p<0.001). Dyspnoea was significantly associated with a higher odds for vulnerability/frailty (per one mMRC adjusted OR 2.01 (95% CI 1.13 to 3.58), p=0.02). CONCLUSIONS: The CFS significantly increases with COVID-19, and dyspnoea is an important risk factor for post-COVID-19 frailty and should be addressed thoroughly.


Assuntos
COVID-19 , Fragilidade , Estudos de Coortes , Dispneia/epidemiologia , Dispneia/etiologia , Feminino , Fragilidade/diagnóstico , Fragilidade/epidemiologia , Força da Mão , Humanos , Masculino , Estudos Prospectivos , Estudos Retrospectivos
14.
Front Immunol ; 12: 613502, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-33968017

RESUMO

In these times of COVID-19 pandemic, concern has been raised about the potential effects of SARS-CoV-2 infection on immunocompromised patients, particularly on those receiving B-cell depleting agents and having therefore a severely depressed humoral response. Convalescent plasma can be a therapeutic option for these patients. Understanding the underlying mechanisms of convalescent plasma is crucial to optimize such therapeutic approach. Here, we describe a COVID-19 patient who was deeply immunosuppressed following rituximab (anti-CD20 monoclonal antibody) and concomitant chemotherapy for chronic lymphoid leukemia. His long-term severe T and B cell lymphopenia allowed to evaluate the treatment effects of convalescent plasma. Therapeutic outcome was monitored at the clinical, biological and radiological level. Moreover, anti-SARS-CoV-2 antibody titers (IgM, IgG and IgA) and neutralizing activity were assessed over time before and after plasma transfusions, alongside to SARS-CoV-2 RNA quantification and virus isolation from the upper respiratory tract. Already after the first cycle of plasma transfusion, the patient experienced rapid improvement of pneumonia, inflammation and blood cell counts, which may be related to the immunomodulatory properties of plasma. Subsequently, the cumulative increase in anti-SARS-CoV-2 neutralizing antibodies due to the three additional plasma transfusions was associated with progressive and finally complete viral clearance, resulting in full clinical recovery. In this case-report, administration of convalescent plasma revealed a stepwise effect with an initial and rapid anti-inflammatory activity followed by the progressive SARS-CoV-2 clearance. These data have potential implications for a more extended use of convalescent plasma and future monoclonal antibodies in the treatment of immunosuppressed COVID-19 patients.


Assuntos
Anticorpos Neutralizantes/sangue , Anticorpos Antivirais/sangue , Tratamento Farmacológico da COVID-19 , COVID-19/imunologia , COVID-19/terapia , Idoso , Anticorpos Neutralizantes/administração & dosagem , Anticorpos Antivirais/administração & dosagem , Antineoplásicos Alquilantes/uso terapêutico , Antineoplásicos Imunológicos/uso terapêutico , Cloridrato de Bendamustina/uso terapêutico , Diabetes Mellitus Tipo 2/complicações , Humanos , Imunização Passiva/métodos , Imunoglobulina A/sangue , Imunoglobulina G/sangue , Imunoglobulina M/sangue , Terapia de Imunossupressão , Leucemia Linfoide/complicações , Leucemia Linfoide/tratamento farmacológico , Masculino , Rituximab/uso terapêutico , SARS-CoV-2/efeitos dos fármacos , SARS-CoV-2/imunologia , Resultado do Tratamento , Soroterapia para COVID-19
16.
Front Med (Lausanne) ; 7: 556218, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-33262990

RESUMO

Background: Noninvasive ventilation (NIV) is accepted as standard of care for chronic hypercapnic respiratory failure (CHRF) and is being increasingly implemented in older subjects. However, little is known regarding the use of NIV on a long-term basis in the very old. The outcomes of this study were: 1/to report the proportion of patients ≥ 75 years old (elderly) among a large group of long-term NIV users and its trend since 2000; 2/to compare this population to a younger population (<75 years old) under long-term NIV in terms of diagnoses, comorbidities, anthropometric data, technical aspects, adherence to and efficiency of NIV. Methods: In a cross-sectional analysis of a multicenter cohort study on patients with CHRF under NIV, diagnoses, comorbidities, technical aspects, adherence to and efficiency of NIV were compared between patients ≥ 75 and <75 years old (chi-square or Welch Student tests). Results: Of a total of 489 patients under NIV, 151 patients (31%) were ≥ 75 years of age. Comorbidities such as systemic hypertension (86 vs. 60%, p < 0.001), chronic heart failure (30 vs. 18%, p = 0.005), and pulmonary hypertension (25 vs. 14%, p = 0.005) were more frequent in older subjects. In the older group, there was a trend for a higher prevalence of chronic obstructive pulmonary disease (COPD) (46 vs. 36%, p = 0.151) and a lower prevalence of neuromuscular diseases (NMD) (19 vs. 11%, p = 0.151), although not significant. Adherence to and efficacy of NIV were similar in both groups (daily use of ventilator: 437 vs. 419 min, p = 0.76; PaCO2: 5.8 vs. 5.9 kPa, p = 0.968). Unintentional leaks were slightly higher in the older group (1.8 vs. 0.6 L/min, p = 0.018). Conclusions: In this cross-sectional study, one third of the population under NIV was ≥ 75 years old. Markers of efficacy of NIV, and adherence to treatment were similar when compared to younger subjects, confirming the feasibility of long-term NIV in the very old. Health-related quality of life was not assessed in this study and further research is needed to address this issue.

17.
Front Med (Lausanne) ; 7: 105, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-32309284

RESUMO

Background: Use of adaptive servo-ventilation (ASV) has been questioned in patients with central sleep apnea (CSA) and chronic heart failure (CHF). This study aims to detail the present use of ASV in clinical practice. Methods: Descriptive, cross-sectional, multicentric study of patients undergoing long term (≥3 months) ASV in the Cantons of Geneva or Vaud (1,288,378 inhabitants) followed by public or private hospitals, private practitioners and/or home care providers. Results: Patients included (458) were mostly male (392; 85.6%), overweight [BMI (median, IQR): 29 kg/m2 (26; 33)], comorbid, with a median age of 71 years (59-77); 84% had been treated by CPAP before starting ASV. Indications for ASV were: emergent sleep apnea (ESA; 337; 73.6%), central sleep apnea (CSA; 108; 23.6%), obstructive sleep apnea (7; 1.5%), and overlap syndrome (6; 1.3%). Origin of CSA was cardiac (n = 30), neurological (n = 26), idiopathic (n = 28), or drug-related (n = 22). Among CSA cases, 60 (56%) patients had an echocardiography within the preceding 12 months; median left ventricular ejection fraction (LVEF) was 62.5% (54-65); 11 (18%) had a LVEF ≤45%. Average daily use of ASV was [mean (SD)] 368 (140) min; 13% used their device <3:30 h. Based on ventilator software, apnea-hypopnea index was normalized in 94% of subjects with data available (94% of 428). Conclusions: Use of ASV has evolved from its original indication (CSA in CHF) to a heterogeneous predominantly male, aged, comorbid, and overweight population with mainly ESA or CSA. CSA in CHF represented only 6.5% of this population. Compliance and correction of respiratory events were satisfactory. Clinical Trial Registration: www.ClinicalTrials.gov, identifier: NCT04054570.

18.
Chest ; 158(1): 279-291, 2020 07.
Artigo em Inglês | MEDLINE | ID: mdl-32243941

RESUMO

BACKGROUND: Noninvasive ventilation (NIV) is standard of care for chronic hypercapnic respiratory failure, but indications, devices, and ventilatory modes are in constant evolution. RESEARCH QUESTION: To describe changes in prevalence and indications for NIV over a 15-year period; to provide a comprehensive report of characteristics of the population treated (age, comorbidities, and anthropometric data), mode of implementation and follow-up, devices, modes and settings used, physiological data, compliance, and data from ventilator software. STUDY DESIGN AND METHODS: Cross-sectional observational study designed to include all subjects under NIV followed by all structures involved in NIV in the Cantons of Geneva and Vaud (1,288,378 inhabitants). RESULTS: A total of 489 patients under NIV were included. Prevalence increased 2.5-fold since 2000 reaching 38 per 100,000 inhabitants. Median age was 71 years, with 31% being > 75 years of age. Patients had been under NIV for a median of 39 months and had an average of 3 ± 1.8 comorbidities; 55% were obese. COPD (including overlap syndrome) was the most important patient group, followed by obesity hypoventilation syndrome (OHS) (26%). Daytime Paco2 was most often normalized. Adherence to treatment was satisfactory, with 8% only using their device < 3.5 h/d. Bilevel positive pressure ventilators in spontaneous/timed mode was the default mode (86%), with a low use of autotitrating modes. NIV was initiated electively in 50% of the population, in a hospital setting in 82%, and as outpatients in 15%. INTERPRETATION: Use of NIV is increasing rapidly in this area, and the population treated is aging, comorbid, and frequently obese. COPD is presently the leading indication followed by OHS. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT04054570; URL: www.clinicaltrials.gov.


Assuntos
Ventilação não Invasiva , Síndrome de Hipoventilação por Obesidade/terapia , Cooperação do Paciente , Seleção de Pacientes , Doença Pulmonar Obstrutiva Crônica/terapia , Adulto , Idoso , Idoso de 80 Anos ou mais , Estudos Transversais , Feminino , Serviços de Assistência Domiciliar , Humanos , Masculino , Pessoa de Meia-Idade , Suíça
19.
Respir Physiol Neurobiol ; 150(1): 75-81, 2006 Jan 25.
Artigo em Inglês | MEDLINE | ID: mdl-16448935

RESUMO

Studying the inspiratory recruitment of the scalenes is clinically relevant, but the interpretation of surface electromyographic (EMG) recordings is difficult. The aim of this study was to optimize an averaging method to analyze the surface EMG activity of the scalenes. Ten healthy subjects were studied. Nasal flow and surface EMG of the right scalene were recorded during 15 min epochs of quiet breathing. In four subjects, needle scalene EMG was also recorded. The flow signal was used to trigger the ensemble averaging of the ventilatory wave forms from 80 consecutive breaths. In eight cases, this evidenced a phasic inspiratory activation of the scalenes and permitted the determination of the electromechanical inspiratory delay (134+/-55 ms) and post-inspiratory activity (811+/-233 ms). When simultaneously available, surface and intramuscular recordings provided identical results. An averaging method triggered from a respiratory flow signal can identify and characterize a low phasic inspiratory activity of the scalenes within a noisy surface signal.


Assuntos
Eletromiografia , Inalação/fisiologia , Músculo Esquelético/fisiologia , Respiração , Processamento de Sinais Assistido por Computador , Adulto , Feminino , Humanos , Masculino
20.
Swiss Med Wkly ; 146: w14305, 2016.
Artigo em Inglês | MEDLINE | ID: mdl-27244600

RESUMO

Pulmonary arterial hypertension (PAH) is a vascular disease of unknown aetiology, characterised by an abnormal thickening of the arterial wall that is responsible for an increase in pulmonary vascular resistance. The haemodynamic consequence of PAH is an increased afterload for the right ventricle and, eventually, right heart failure. When untreated, PAH has a grim prognosis with a median survival of about 2 to 4 years from diagnosis. In the last 10 years new orally administered compounds have demonstrated clinical efficacy in controlled trials using various surrogate endpoints to survival. Although the disease remains without cure until now, the available phase III trials have allowed evidence-based recommendations for the medical management of these patients to be established. It appears, however, that none of the compounds from the three main therapeutic classes, endothelin receptor antagonists, agents acting on the nitric oxide-cyclic guanosine monophosphate pathway (including phosphodiesterase type 5 inhibitors and guanylate cyclase stimulator), and prostanoid receptor agonists are able alone to control disease progression in every patient. Therefore combination therapy with two or three drugs may be necessary in a significant number of patients in order to maintain patients in, or bring them to, a low risk profile. Several recent studies have now validated this approach for specific double or triple drug regimens. It remains, however, unclear whether an upfront combination is preferable to a sequential step-up approach based on clinical response. In addition, some specific combination therapies have failed to demonstrate superiority to single drug alone in randomised controlled trials. Besides PAH-specific treatment, the place of nonspecific pharmaceutical and nonpharmaceutical treatment has been also recently clarified.


Assuntos
Anti-Hipertensivos/uso terapêutico , Terapia Combinada/métodos , Hipertensão Pulmonar/tratamento farmacológico , Hipertensão Pulmonar/fisiopatologia , Antagonistas dos Receptores de Endotelina , Humanos , Inibidores de Fosfodiesterase , Prognóstico , Ensaios Clínicos Controlados Aleatórios como Assunto
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA